ETH Zurich Pioneers CRISPR-Cas Gene Editing to Uncover Cancer-Causing Mutations

Researchers have combined base and prime editing techniques to analyze genetic variants in the EGFR gene, revealing new insights into cancer development and drug resistance.

• ETH Zurich's innovative use of CRISPR-Cas technology allows for the creation of tens of thousands of gene variants to study cancer development.
• The research focuses on the EGFR gene, which is critical in various cancers, including lung, brain, and breast cancer.
• By combining base and prime editing, researchers can systematically explore mutations that may cause cancer or confer drug resistance.
• The study identified ten previously uncertain EGFR variants as significant in cancer progression and drug resistance.
• Six new gene variants linked to cancer were discovered, potentially guiding future oncological research and treatment strategies.

2 Articles

GEN Technology Networks